AIDS and Cancer Specimen Resource (ACSR)
艾滋病和癌症样本资源 (ACSR)
基本信息
- 批准号:10477357
- 负责人:
- 金额:$ 483.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-23 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS Malignancy ConsortiumAIDS related cancerAIDS/HIV problemAcquired Immunodeficiency SyndromeAdherenceAdultAffectAfrica South of the SaharaAfrican AmericanAreaArizonaBasic ScienceBiologicalBiological Specimen BanksCaribbean regionCause of DeathCessation of lifeClinicalClinical DataClinical ResearchClinical TrialsCollaborationsCollectionComplexConsentDataData PoolingDevelopmentEconomic BurdenEnsureEpidemicEquipment and supply inventoriesEvolutionFosteringFreezingFundingGeographic LocationsGoalsGrowthHIVHeadHealthHepatitis B VirusHepatitis C virusHispanic AmericansHodgkin DiseaseHuman Herpesvirus 4Human PapillomavirusIncidenceIndividualInfectionInformaticsInstitutionInternationalInvestigationKaposi SarcomaLatin AmericaLatin AmericanLeadershipLinkLiquid substanceMalignant NeoplasmsMalignant neoplasm of anusMalignant neoplasm of cervix uteriMalignant neoplasm of lungMarketingMedical EconomicsMethodologyMissionMorbidity - disease rateNetwork InfrastructureNon-Hodgkin&aposs LymphomaOutcomePathogenesisPathologicPatientsPersonsPlayPrevalenceProcessPublic HealthReportingResearchResearch PersonnelResearch SupportResourcesRiskRisk FactorsRoleSample SizeSamplingScienceScientistSiteSmokingSpecimenStandardizationStructureTechnologyTestingTimeTissue SampleTranslational ResearchTumor TissueU-Series Cooperative AgreementsUnited StatesUnited States National Institutes of HealthUniversitiesViralWashingtonWorkaging populationantiretroviral therapybiobankbiological specimen archivescancer epidemiologycancer riskcancer specimen resourcecancer therapycancer typeco-infectionepidemiologic datafitnessimmune functioninformatics infrastructuremenmortalitynew technologynovelolder patientoutreachprogramssample collectionskillssuccesstumor microenvironmentvirtualvirtual repositoryvirus related cancerworking group
项目摘要
Abstract
The AIDS epidemic, initially recognized in the early 1980's, currently affects more than 35 million people
worldwide. Infection with the human immunodeficiency virus (HIV) is associated with a wide range of long term
health complications including the development of cancer, currently a major cause of death among persons living
with HIV/AIDS. The early form of the AIDS and Cancer Specimen Resource (ACSR) was established in 1994 as
a cooperative agreement with the NCI with a mission to provide high quality biospecimens to researchers, a
mission still paramount for the current ACSR.
Principle investigators (MPIs) from the two legacy sites (GWU and UCSF) oversee the function of the ACSR to
ensure the adherence to NCI best practices in this multinational program. The ACSR is currently the custodian
for specimen collections from more than 20,000 individuals and makes these biospecimens available to eligible
researchers studying HIV and cancer through an established specimen application process. In the past five
years, investigators from more than 50 institutions have received research material from the ACSR. In addition,
the ACSR has provided the centralized biospecimen collection and distribution functions for the AIDS Malignancy
Consortium (AMC), which represents the NCI-funded international network of more than 30 clinical institutions
involved in testing novel cancer therapies in HIV-infected individuals. The ACSR is structured into regional
biospecimen repositories (RBRs) located in distinct geographical regions that reflect the US and global HIV
epidemic and are unified (virtually) by an informatics infrastructure managed by the Hub for Integrated
Informatics and Research Support (HIIRS). The RBRs are distinct but complementary in their diverse functions,
with collaborative interactions fostered through the Governing Committee and ACSR-wide Working Groups that
accomplish activities related to Science and Technology, Marketing and Outreach, Informatics, and Quality
Management.
As the HIV epidemic has evolved the types of cancers and the technologies used to study them have also
changed. The newly reconfigured ACSR will have two divisions, both focused on obtaining the most important
well-annotated (demographic, clinical, pathological and outcomes data) biospecimens for research as defined
by investigator inquiries and the ACSR's scientific advisory board. The two MPIs, respectively will head the
national and international AMC support program and the scientific direction of the ACSR. Both MPIs will work
within the structure of the ACSR to obtain and provide to researcher's specimens most important for research in
the current epidemic. Specific Aims include: 1) Acquire, store, and equitably distribute tumor tissues and
biological fluids from individuals with HIV-associated malignancies (AIDS-defining cancers and non-AIDS
defining cancers) to meet the biospecimen needs of researchers in HIV-associated malignancies; and 2)
Promote the success of AMC clinical trials through mutually beneficial collaborations.
抽象的
艾滋病流行于 1980 年代初首次被发现,目前影响超过 3500 万人
全世界。人类免疫缺陷病毒 (HIV) 感染与多种长期疾病有关
健康并发症,包括癌症的发展,目前是活着的人死亡的一个主要原因
患有艾滋病毒/艾滋病。艾滋病和癌症样本资源 (ACSR) 的早期形式成立于 1994 年,名称为
与 NCI 达成合作协议,其使命是为研究人员提供高质量的生物样本,
对于当前的 ACSR 来说,使命仍然至关重要。
来自两个遗留站点(GWU 和 UCSF)的原理研究者 (MPI) 负责监督 ACSR 的功能,以
确保该跨国计划遵守 NCI 最佳实践。目前托管人为ACSR
收集超过 20,000 个人的样本,并将这些生物样本提供给符合条件的人
研究人员通过既定的样本应用流程研究艾滋病毒和癌症。在过去的五年里
多年来,来自 50 多个机构的研究人员收到了来自 ACSR 的研究材料。此外,
ACSR为艾滋病恶性肿瘤提供集中的生物样本采集和分发功能
联盟 (AMC),代表 NCI 资助的由 30 多家临床机构组成的国际网络
参与在艾滋病毒感染者中测试新型癌症疗法。 ACSR 的结构分为区域
生物样本库 (RBR) 位于不同的地理区域,反映了美国和全球的艾滋病毒情况
流行病,并由综合中心管理的信息学基础设施(实际上)统一
信息学和研究支持(HIIRS)。 RBR 各不相同,但其不同的功能是互补的,
通过理事会和 ACSR 范围内的工作组促进协作互动,
完成与科学技术、营销和外展、信息学和质量相关的活动
管理。
随着艾滋病毒流行的发展,癌症的类型和用于研究癌症的技术也发生了变化。
改变了。新重组的钢绞线将有两个部门,两个部门都专注于获得最重要的信息
注释明确的(人口统计、临床、病理和结果数据)生物样本,用于定义的研究
通过调查员调查和 ACSR 的科学顾问委员会。两个 MPI 将分别领导
国家和国际 AMC 支持计划以及 ACSR 的科学方向。两个 MPI 都可以工作
在 ACSR 的结构内,获取并向研究人员提供对研究最重要的样本
当前的疫情。具体目标包括:1) 获取、储存和公平分配肿瘤组织和
来自患有艾滋病毒相关恶性肿瘤(艾滋病定义的癌症和非艾滋病)的个体的生物体液
定义癌症)以满足艾滋病毒相关恶性肿瘤研究人员的生物样本需求;和 2)
通过互利合作促进AMC临床试验的成功。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Michael Bethony其他文献
Jeffrey Michael Bethony的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Michael Bethony', 18)}}的其他基金
Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists
不同 TLR 激动剂钩虫疫苗功效的对照感染试验
- 批准号:
10556618 - 财政年份:2017
- 资助金额:
$ 483.07万 - 项目类别:
Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists
不同 TLR 激动剂钩虫疫苗功效的对照感染试验
- 批准号:
9914089 - 财政年份:2017
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8665533 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8828108 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8258216 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8444662 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8628789 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
PRODUCT DEVELOPMENT OF A MEMBRANE TETRASPANIN VACCINE AGAINST SCHISTOSOMIASIS
血吸虫病膜四跨膜疫苗的产品开发
- 批准号:
8186912 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
- 批准号:
8025569 - 财政年份:2011
- 资助金额:
$ 483.07万 - 项目类别:
相似海外基金
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa
马拉维和南非的艾滋病毒癌症筛查和预后创新,包括卡波西肉瘤、宫颈癌和淋巴瘤
- 批准号:
10434858 - 财政年份:2020
- 资助金额:
$ 483.07万 - 项目类别:
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa
马拉维和南非的艾滋病毒癌症筛查和预后创新,包括卡波西肉瘤、宫颈癌和淋巴瘤
- 批准号:
10238155 - 财政年份:2020
- 资助金额:
$ 483.07万 - 项目类别:
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa
马拉维和南非的艾滋病毒癌症筛查和预后创新,包括卡波西肉瘤、宫颈癌和淋巴瘤
- 批准号:
10084552 - 财政年份:2020
- 资助金额:
$ 483.07万 - 项目类别: